Carisma Therapeutics (CARM) Institutional Ownership $0.42 -0.02 (-5.35%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends Institutional Ownership Changes (13F Filings) for Carisma Therapeutics (NASDAQ:CARM)CurrentInstitutional OwnershipPercentage44.27%Number ofInstitutional Buyers(last 12 months)4TotalInstitutional Inflows(last 12 months)$1.20MNumber ofInstitutional Sellers(last 12 months)5TotalInstitutional Outflows(last 12 months)$2.62M Get CARM Insider Trade Alerts Want to know when executives and insiders are buying or selling Carisma Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data CARM Institutional Buying and Selling by Quarter Ad Weiss RatingsBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $125,000 by the end of his first month in office.This could be his favorite coin. Carisma Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails11/19/2024 Barclays PLC549,305$539K0.0%+3,661,933.3%1.316% 11/16/2024 Geode Capital Management LLC259,184$254K0.0%-8.5%0.621% 11/15/2024 Barclays PLC549,305$539K0.0%+3,661,933.3%1.316% 11/15/2024 Wexford Capital LP34,861$34K0.0%+75.5%0.083% 9/16/2024 Point72 Asia Singapore Pte. Ltd.26,006$40K0.0%N/A0.063% 8/15/2024 Point72 Asia Singapore Pte. Ltd.26,006$40K0.0%N/A0.063% 8/15/2024 TPG GP A LLC842,031$1.28M0.0%-42.0%2.027% 8/9/2024 Renaissance Technologies LLC139,360$212K0.0%-38.3%0.335% 5/10/2024 Vanguard Group Inc.1,579,961$3.59M0.0%+0.7%3.803% 5/7/2024 Empowered Funds LLC26,984$61K0.0%-43.9%0.065% 2/14/2024 Trustees of The University of Pennsylvania1,252,107$3.67M10.3%-28.9%3.102% 10/13/2023 SG Americas Securities LLC13,653$58K0.0%N/A0.034% 9/21/2023 Barclays PLC5,312$47K0.0%N/A0.013% 8/4/2023 American International Group Inc.12,834$113K0.0%N/A0.032% 7/27/2023EA Series Trust40,434$355K0.0%N/A0.100% 6/15/2023 Trustees of The University of Pennsylvania2,182,812$6.77M6.6%N/A5.422% 5/15/2023 Wittenberg Investment Management Inc.46,703$145K0.1%N/A0.459% 5/12/2023 Deuterium Capital Management LLC51,256$159K0.2%N/A0.504% 5/10/2023 Connor Clark & Lunn Investment Management Ltd.14,796$46K0.0%N/A0.145% 5/3/2023 Jump Financial LLC17,542$54K0.0%N/A0.172% 5/1/2023 Virtu Financial LLC15,335$48K0.0%N/A0.151% 4/27/2023Stratos Wealth Partners LTD.19,899$62K0.0%N/A0.195% 4/24/2023 Blodgett Wealth Advisors LLC29,660$92K0.1%N/A0.291% 4/14/2023 BML Capital Management LLC411,398$1.28M1.1%N/A4.041% (Data available from 1/1/2016 forward) CARM Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of CARM shares? During the previous two years, 20 institutional investors and hedge funds held shares of Carisma Therapeutics. The most heavily invested institutionals were Trustees of The University of Pennsylvania ($3.67M), Vanguard Group Inc. ($3.59M), TPG GP A LLC ($1.28M), BML Capital Management LLC ($1.28M), Barclays PLC ($539K), EA Series Trust ($355K), and Geode Capital Management LLC ($254K).Learn more on CARM's institutional investors. What percentage of Carisma Therapeutics stock is owned by institutional investors? 44.27% of Carisma Therapeutics stock is owned by institutional investors. Learn more on CARM's institutional investor holdings. Which institutional investors have been buying Carisma Therapeutics stock? Of the 16 institutional investors that purchased Carisma Therapeutics stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Trustees of The University of Pennsylvania ($2.18M), Barclays PLC ($1.10M), BML Capital Management LLC ($411.40K), Point72 Asia Singapore Pte. Ltd. ($52.01K), Deuterium Capital Management LLC ($51.26K), Wittenberg Investment Management Inc. ($46.70K), and EA Series Trust ($40.43K). How much institutional buying is happening at Carisma Therapeutics? Institutional investors have bought a total of 4,038,426 shares in the last 24 months. This purchase volume represents approximately $10.42M in transactions. Which Carisma Therapeutics major shareholders have been selling company stock? The following institutional investors have sold Carisma Therapeutics stock in the last 24 months: TPG GP A LLC ($609.85K), Trustees of The University of Pennsylvania ($507.74K), Renaissance Technologies LLC ($86.64K), Geode Capital Management LLC ($24.22K), and Empowered Funds LLC ($21.15K). How much institutional selling is happening at Carisma Therapeutics? Institutional investors have sold a total of 1,249,596 shares in the last 24 months. This volume of shares sold represents approximately $2.62M in transactions. Related Companies Generation Bio Major Shareholders FibroBiologics Major Shareholders PDS Biotechnology Major Shareholders Ovid Therapeutics Major Shareholders Aerovate Therapeutics Major Shareholders Werewolf Therapeutics Major Shareholders ESSA Pharma Major Shareholders Repare Therapeutics Major Shareholders Annovis Bio Major Shareholders OptiNose Major Shareholders This page (NASDAQ:CARM) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredVideo: Blindfolded Man Gets Into a Cybertruck… What Happens Next Will Shock You“Hi, I’m Jeff Brown… Even though I can’t see a thing… I’m about to get in this Cybertruck and drive up t...Brownstone Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Carisma Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Carisma Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.